Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.

Paller C, Pu H, Begemann DE, Wade CA, Hensley PJ, Kyprianou N.

Prostate. 2018 Aug 28. doi: 10.1002/pros.23708. [Epub ahead of print]

PMID:
30155899
2.

Profiles of Radioresistance Mechanisms in Prostate Cancer.

Chaiswing L, Weiss HL, Jayswal RD, Clair DKS, Kyprianou N.

Crit Rev Oncog. 2018;23(1-2):39-67. doi: 10.1615/CritRevOncog.2018025946.

PMID:
29953367
3.

Personalization of prostate cancer therapy through phosphoproteomics.

Yang W, Freeman MR, Kyprianou N.

Nat Rev Urol. 2018 Aug;15(8):483-497. doi: 10.1038/s41585-018-0014-0. Review.

PMID:
29752463
4.

Profiling Prostate Cancer Therapeutic Resistance.

Wade CA, Kyprianou N.

Int J Mol Sci. 2018 Mar 19;19(3). pii: E904. doi: 10.3390/ijms19030904. Review.

5.

Nuclear spindles pave the way to metastasis.

Hensley PJ, Kyprianou N.

Oncotarget. 2017 Dec 27;9(16):12544-12545. doi: 10.18632/oncotarget.23728. eCollection 2018 Feb 27. No abstract available.

6.

Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.

Begemann D, Anastos H, Kyprianou N.

Int J Urol. 2018 Apr;25(4):318-326. doi: 10.1111/iju.13505. Epub 2018 Jan 17. Review.

PMID:
29345000
7.

Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.

Cao Z, Koochekpour S, Strup SE, Kyprianou N.

Oncotarget. 2017 Jul 28;8(45):78507-78519. doi: 10.18632/oncotarget.19659. eCollection 2017 Oct 3.

8.

Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.

Stark TW, Hensley PJ, Spear A, Pu H, Strup SS, Kyprianou N.

Prostate. 2017 Dec;77(16):1583-1591. doi: 10.1002/pros.23435. Epub 2017 Oct 23.

PMID:
29063620
9.

Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis.

Pu H, Begemann DE, Kyprianou N.

Endocrinology. 2017 Jun 1;158(6):1612-1622. doi: 10.1210/en.2017-00086.

10.

Mechanisms of Therapeutic Resistance in Prostate Cancer.

Nakazawa M, Paller C, Kyprianou N.

Curr Oncol Rep. 2017 Feb;19(2):13. doi: 10.1007/s11912-017-0568-7. Review.

11.

Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.

Cao Z, Livas T, Kyprianou N.

Crit Rev Oncog. 2016;21(3-4):155-168. Review.

12.

TGF-β Conveys Undesirable Side Effects of Androgen Depletion.

Kyprianou N.

Endocrinology. 2016 Nov;157(11):4206-4208. No abstract available.

13.

Prostate cancer: Kinases and CHIPS sign-off personalization of therapy.

Kyprianou N.

Nat Rev Urol. 2016 Nov;13(11):636-637. doi: 10.1038/nrurol.2016.194. Epub 2016 Oct 11. No abstract available.

PMID:
27725640
14.

Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer.

Hensley PJ, Zetter D, Horbinski CM, Strup SE, Kyprianou N.

Hum Pathol. 2016 Nov;57:68-77. doi: 10.1016/j.humpath.2016.06.020. Epub 2016 Jul 8.

15.

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S.

Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016. doi: 10.1158/1078-0432.CCR-16-0137. [Epub ahead of print] Retraction in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3973.

PMID:
27458247
16.

Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.

Nakazawa M, Kyprianou N.

J Steroid Biochem Mol Biol. 2017 Feb;166:84-90. doi: 10.1016/j.jsbmb.2016.05.007. Epub 2016 May 14. Review.

PMID:
27189666
17.

Inflammation in prostate cancer progression and therapeutic targeting.

Stark T, Livas L, Kyprianou N.

Transl Androl Urol. 2015 Aug;4(4):455-63. doi: 10.3978/j.issn.2223-4683.2015.04.12. Review.

18.

Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.

Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N.

Cancer Res. 2016 Feb 15;76(4):912-26. doi: 10.1158/0008-5472.CAN-15-2078. Epub 2015 Dec 8.

19.

Epithelial-mesenchymal transition in prostatic disease.

Broster SA, Kyprianou N.

Future Oncol. 2015;11(23):3197-206. doi: 10.2217/fon.15.253. Epub 2015 Nov 9. Review.

PMID:
26551285
20.

CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion.

Zhou P, Erfani S, Liu Z, Jia C, Chen Y, Xu B, Deng X, Alfáro JE, Chen L, Napier D, Lu M, Huang JA, Liu C, Thibault O, Segal R, Zhou BP, Kyprianou N, Horbinski C, Yang XH.

Oncotarget. 2015 Oct 6;6(30):29675-93. doi: 10.18632/oncotarget.4896.

21.

Therapeutic challenges in renal cell carcinoma.

Penticuff JC, Kyprianou N.

Am J Clin Exp Urol. 2015 Aug 8;3(2):77-90. eCollection 2015. Review.

22.

Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.

Martin SK, Kyprianou N.

Adv Cancer Res. 2015;127:123-58. doi: 10.1016/bs.acr.2015.03.001. Epub 2015 Mar 29. Review.

PMID:
26093899
23.

Mechanisms navigating the TGF-β pathway in prostate cancer.

Cao Z, Kyprianou N.

Asian J Urol. 2015 Jan;2(1):11-18. doi: 10.1016/j.ajur.2015.04.011. Epub 2015 Apr 16.

24.

The promise of novel molecular markers in bladder cancer.

Miremami J, Kyprianou N.

Int J Mol Sci. 2014 Dec 22;15(12):23897-908. doi: 10.3390/ijms151223897. Review.

25.

N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Martin SK, Banuelos CA, Sadar MD, Kyprianou N.

Mol Oncol. 2014 Nov 15. pii: S1574-7891(14)00263-4. doi: 10.1016/j.molonc.2014.10.014. [Epub ahead of print]

26.

Cytoskeleton targeting value in prostate cancer treatment.

Martin SK, Kamelgarn M, Kyprianou N.

Am J Clin Exp Urol. 2014 Apr 5;2(1):15-26. eCollection 2014. Review.

27.

Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.

Grant CM, Kyprianou N.

Transl Androl Urol. 2013 Sep 1;2(3):202-211.

28.

The fringe benefits of cloning cancer.

Kyprianou N.

Sci Transl Med. 2014 Sep 17;6(254):254fs36. doi: 10.1126/scitranslmed.3010174.

PMID:
25232174
29.

A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).

Lacy JM, Kyprianou N.

Oncol Lett. 2014 Oct;8(4):1391-1396. Epub 2014 Jul 28.

30.

PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.

Pu H, Horbinski C, Hensley PJ, Matuszak EA, Atkinson T, Kyprianou N.

Carcinogenesis. 2014 Nov;35(11):2592-601. doi: 10.1093/carcin/bgu183. Epub 2014 Aug 30.

31.

The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.

Liu Y, Gilbert MR, Kyprianou N, Rangnekar VM, Horbinski C.

Acta Neuropathol. 2014 Nov;128(5):723-32. doi: 10.1007/s00401-014-1334-7. Epub 2014 Aug 19.

32.

Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.

Kahn B, Collazo J, Kyprianou N.

Int J Biol Sci. 2014 Jun 1;10(6):588-95. doi: 10.7150/ijbs.8671. eCollection 2014.

33.

Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer.

Collazo J, Zhu B, Larkin S, Martin SK, Pu H, Horbinski C, Koochekpour S, Kyprianou N.

Cancer Res. 2014 Apr 15;74(8):2362-73. doi: 10.1158/0008-5472.CAN-13-3058. Epub 2014 Feb 7. Erratum in: Cancer Res. 2018 Sep 1;78(17):5180.

34.

Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells.

Hensley PJ, Desiniotis A, Wang C, Stromberg A, Chen CS, Kyprianou N.

PLoS One. 2014 Jan 31;9(1):e86238. doi: 10.1371/journal.pone.0086238. eCollection 2014.

35.

Therapeutic value of quinazoline-based compounds in prostate cancer.

Bilbro J, Mart M, Kyprianou N.

Anticancer Res. 2013 Nov;33(11):4695-700. Review.

36.

Autophagy and oxidative stress in gliomas with IDH1 mutations.

Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N, Horbinski C.

Acta Neuropathol. 2014 Feb;127(2):221-33. doi: 10.1007/s00401-013-1194-6. Epub 2013 Oct 23.

37.

p27 Stands-up-to-cancer: UPS nuclear service stops.

Fiandalo MV, Kyprianou N.

Endocrinology. 2013 Nov;154(11):3970-3. doi: 10.1210/en.2013-1873. No abstract available.

38.

Molecular signatures in urologic tumors.

Larkin S, Kyprianou N.

Int J Mol Sci. 2013 Sep 6;14(9):18421-36. doi: 10.3390/ijms140918421. Review.

39.

Targeting caspases in cancer therapeutics.

Hensley P, Mishra M, Kyprianou N.

Biol Chem. 2013 Jul;394(7):831-43. doi: 10.1515/hsz-2013-0128. Review.

40.

Proteasomal regulation of caspase-8 in cancer cell apoptosis.

Fiandalo MV, Schwarze SR, Kyprianou N.

Apoptosis. 2013 Jun;18(6):766-76. doi: 10.1007/s10495-013-0821-y.

41.

Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.

Matuszak EA, Kyprianou N.

BJU Int. 2013 Jan;111(1):6-7. doi: 10.1111/j.1464-410X.2012.11566.x. Epub 2012 Oct 26. No abstract available.

42.

Caspase control: protagonists of cancer cell apoptosis.

Fiandalo MV, Kyprianou N.

Exp Oncol. 2012 Oct;34(3):165-75. Review.

43.

Emerging biomarkers of prostate cancer (Review).

Martin SK, Vaughan TB, Atkinson T, Zhu H, Kyprianou N.

Oncol Rep. 2012 Aug;28(2):409-17. doi: 10.3892/or.2012.1832. Epub 2012 May 25. Review.

44.

Advances in the design and synthesis of prazosin derivatives over the last ten years.

Desiniotis A, Kyprianou N.

Expert Opin Ther Targets. 2011 Dec;15(12):1405-18. doi: 10.1517/14728222.2011.641534. Epub 2011 Dec 13. Review.

45.

Significance of talin in cancer progression and metastasis.

Desiniotis A, Kyprianou N.

Int Rev Cell Mol Biol. 2011;289:117-47. doi: 10.1016/B978-0-12-386039-2.00004-3. Review.

46.

Modeling prostate cancer in mice: limitations and opportunities.

Hensley PJ, Kyprianou N.

J Androl. 2012 Mar-Apr;33(2):133-44. doi: 10.2164/jandrol.111.013987. Epub 2011 Jun 16. Review.

47.

EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer.

Zhu H, Zhao J, Zhu B, Collazo J, Gal J, Shi P, Liu L, Ström AL, Lu X, McCann RO, Toborek M, Kyprianou N.

Prostate. 2012 Jan;72(1):72-81. doi: 10.1002/pros.21408. Epub 2011 May 11.

48.

Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis.

Matuszak EA, Kyprianou N.

Expert Rev Endocrinol Metab. 2011 May;6(3):469-482.

49.

Detection of microRNAs in prostate cancer cells by microRNA array.

Tang X, Tang X, Gal J, Kyprianou N, Zhu H, Tang G.

Methods Mol Biol. 2011;732:69-88. doi: 10.1007/978-1-61779-083-6_6.

PMID:
21431706
50.

Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma.

Sakamoto S, Schwarze S, Kyprianou N.

Eur Urol. 2011 May;59(5):734-44. doi: 10.1016/j.eururo.2010.12.038. Epub 2011 Jan 12.

Supplemental Content

Loading ...
Support Center